1. Catalog
  2. Nodes
  3. a(CHEBI:pioglitazone)

a(CHEBI:pioglitazone)

Equivalencies: 0 | Classes: 0 | Children: 0 | Explore

Entity

Name
pioglitazone
Namespace
chebi
Namespace Version
20180828
Namespace URL
https://raw.githubusercontent.com/pharmacome/terminology/1b20f0637c395f8aa89c2e2e342d7b704062c242/external/chebi-names.belns

Appears in Networks 2

Nuclear receptors as therapeutic targets for Alzheimer's disease. v1.0.0

Clearance of Amyloid Beta and Tau in Alzheimer’s Disease:from Mechanisms to Therapy v1.0.1

In-Edges 0

Out-Edges 11

a(CHEBI:pioglitazone) increases act(p(HGNC:PPARG)) View Subject | View Object

The synthetic TZD PPAR-g agonists are widely prescribed for the treatment of type 2 diabetes mellitus, and have also been shown to be efficacious in a number of CNS disease models [21]. Currently, two TZD agonists, Actos (pioglitazone) and Avandia (rosiglitazone), are FDA approved for the treatment of diabetes. PubMed:21718217

Appears in Networks:
Annotations
Confidence
High

a(CHEBI:pioglitazone) decreases path(MESH:"Diabetes Mellitus, Type 2") View Subject | View Object

The synthetic TZD PPAR-g agonists are widely prescribed for the treatment of type 2 diabetes mellitus, and have also been shown to be efficacious in a number of CNS disease models [21]. Currently, two TZD agonists, Actos (pioglitazone) and Avandia (rosiglitazone), are FDA approved for the treatment of diabetes. PubMed:21718217

Appears in Networks:
Annotations
Confidence
High

a(CHEBI:pioglitazone) decreases a(HBP:HBP00018) View Subject | View Object

When a higher dose of pioglitazone (7 days/40 mg/kg/day) was used in 10-monthold transgenic mice overexpressing the APP V717I mutation, a 20-- 25% decrease in plaque burden was observed with significant reduction in Ab42 levels within the brains of these animals [61]. PubMed:21718217

Appears in Networks:
Annotations
Confidence
High

a(CHEBI:pioglitazone) decreases a(HBP:HBP00018) View Subject | View Object

Furthermore, the treatment of APP/PS1 mouse model of AD with pioglitazone (80 mg/kg/day) for 9 days lowered plaque burden by ~ 50% and reversed behavioral deficits in contextual fear conditioning assay. PubMed:21718217

Appears in Networks:
Annotations
Confidence
High

a(CHEBI:pioglitazone) decreases a(CHEBI:"amyloid-beta polypeptide 42") View Subject | View Object

When a higher dose of pioglitazone (7 days/40 mg/kg/day) was used in 10-monthold transgenic mice overexpressing the APP V717I mutation, a 20-- 25% decrease in plaque burden was observed with significant reduction in Ab42 levels within the brains of these animals [61]. PubMed:21718217

Appears in Networks:
Annotations
Confidence
High

a(CHEBI:pioglitazone) increases bp(GO:behavior) View Subject | View Object

Furthermore, the treatment of APP/PS1 mouse model of AD with pioglitazone (80 mg/kg/day) for 9 days lowered plaque burden by ~ 50% and reversed behavioral deficits in contextual fear conditioning assay. PubMed:21718217

Appears in Networks:
Annotations
Confidence
High

a(CHEBI:pioglitazone) increases p(MGI:Abca1) View Subject | View Object

Significantly, the levels of ABCA1 and ApoE were elevated in the brains of these animals [66]. PubMed:21718217

Appears in Networks:
Annotations
Confidence
Medium

a(CHEBI:pioglitazone) increases p(MGI:Apoe) View Subject | View Object

Significantly, the levels of ABCA1 and ApoE were elevated in the brains of these animals [66]. PubMed:21718217

Appears in Networks:
Annotations
Confidence
Medium

a(CHEBI:pioglitazone) increases bp(GO:memory) View Subject | View Object

In this study, pioglitazone treatment was shown to improve memory and cognition in these patients [67,68]. PubMed:21718217

Appears in Networks:
Annotations
Confidence
High

a(CHEBI:pioglitazone) increases bp(GO:cognition) View Subject | View Object

In this study, pioglitazone treatment was shown to improve memory and cognition in these patients [67,68]. PubMed:21718217

Appears in Networks:
Annotations
Confidence
High

a(CHEBI:pioglitazone) decreases a(CHEBI:"amyloid-beta") View Subject | View Object

Moreover, pioglitazone seems to be an effective therapeutic approach targeting Aβ clearance via similar mechanisms to those of rosiglitazone (Mandrekar-Colucci et al. 2012) PubMed:29626319

Appears in Networks:

About

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.